MK 473

Subscribe to Selected New Research on MK 473

5 relevant articles (1 outcomes, 0 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd without isomeric designation

Also Known As:

(2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid; 2-((2-cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy)acetic acid; IAA 94; IAA-94; MK 473, (+)-isomer; MK 473, (+-)-isomer; MK 473, (-)-isomer; MK 473, sodium salt; MK 473, sodium salt, (+)-isomer; MK 473, sodium salt, (-)-isomer; MK-473; indanyloxyacetic acid

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Related Diseases

1.	Infarction 08/15/2002 - "We confirmed that IAA-94 blocked IPC-, APNEA- and PMA-induced protection against infarction in the isolated heart model" Order ALL the reference details at left...
2.	Apnea 08/15/2002 - "We confirmed that IAA-94 blocked IPC-, APNEA- and PMA-induced protection against infarction in the isolated heart model" 08/15/2002 - "CCPA, APNEA and PMA significantly (P<0.01) reduced the % of dead cardiomyocytes (by trypan blue staining) after 45 min SI/60 min SR, as compared to controls, while IAA-94 abolished this protection but did not affect PKCepsilon translocation by IPC" Order ALL the reference details at left...
3.	Ischemia 08/15/2002 - "RESULTS: Indanyloxyacetic acid 94, a selective Cl(-) channel inhibitor that produced substantial inhibition of the regulatory volume decrease (RVD) when given at 10 microM concentration in cultured cardiomyocytes, was administered before ischemia to block RVD through Cl(-) channel inhibition" 12/01/2000 - "NPPB and IAA-94 at 1 microM and 10 microM, respectively (the doses used in a previous report), did not affect coronary flow, heart rate and developed pressure, and also did not prevent the infarct size reduction of ischemic preconditioning with 5 min global ischemia/10 min reperfusion preceding 30 min of regional ischemia and 120 min of reperfusion [11" Order ALL the reference details at left...
4.	Hypertension (High Blood Pressure) 11/01/1986 - "New diuretics introduced into clinical medicine during the past decade include potent new loop diuretics such as bumetanide and piretanide, the uricosuric indanyloxyacetic acid derivative indacrinone, and a new generation of sulfamoyl diuretics such as indapamide and xipamide, which are recommended primarily for the treatment of hypertension" Order ALL the reference details at left...
5.	Anoxia (Hypoxia) 01/01/2006 - "The Clca channel blockers niflumic acid (NFA) and indanyloxyacetic acid (IAA-94) exerted inhibitory effects on acute hypoxia-evoked contractions in the pulmonary artery" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)
2.	Xipamide
3.	Trypan Blue
4.	Niflumic Acid
5.	Indapamide
6.	Diuretics
7.	Dihydrotachysterol (AT 10)
8.	Bumetanide (Bumex)
9.	5-nitro-2-(3-phenylpropylamino)benzoic acid
10.	piretanide

Best Treatments:
Research Summary Report
on Infarction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 457 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>